



ISEV2027 ABSTRACT SUBMISSION GUIDELINES

Introduction

The abstract submission guidelines for the ISEV2027 Annual Meeting are intended to provide clear instructions for submitting an abstract. You are kindly requested to carefully read the guidelines below before starting the submission process. ISEV and the ISEV2027 International Organizing Committee (IOC) maintain the right to reject any abstract that does not conform to these guidelines.

Key dates:

Abstract Close	Monday, January 11, 2027, at 11:59pm EST
Author Notifications	Monday, February 8, 2027
Presenting Author of Abstracts Registration Deadline	Monday, March 1, 2027

General abstract guidelines

1. Please consult the Minimal Information for Studies of EVs ([MISEV2023](#) – Linked Here) and ensure that your abstract is responsive to the guidelines, including on nomenclature, sample processing, separation, characterization, functional studies, and reporting.
2. The title of the abstract should not exceed 210 characters, and the overall abstract (including title) should not exceed 2,000 characters.
3. Capitalize only the first letter of the first word of the title (unless for abbreviations or proper nouns) and do not end the title with a period (“.”). Do not include quotation marks.
4. The submission portal will include separate categories for Introduction, Methods, Results, and Summary/Conclusions. Please organize your abstract according to this structure.
5. The abstract must contain primary scientific or clinical data that has not been published elsewhere and has not been presented previously at an ISEV meeting. Do not partition results from the same study into multiple abstracts, and do not submit a copy or close copy of an abstract under more than one theme.
6. The abstract submitter is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.
7. Clearly indicate molecular findings with consensus names, not generic identifiers like “Protein X” and “miRNA Y”. Abstracts without these details may be rejected. Please note if a patent is pending and therefore limiting information disclosure.
8. Submitted abstracts on human subjects must have ethical approval and state whether informed consent was obtained. Animal studies need to be approved by the relevant animal use committees.
9. If off-label/unlicensed use of drugs was involved in the study, please state this clearly
10. Indicate if the research was performed or supported by a for-profit entity (e.g. industrial partner). Abstracts must contain scientific content. Out of fairness to ISEV sponsors, abstracts submitted by industry representatives may undergo additional review of the scientific content and may or may not be accepted. If you are an industry representative, kindly consider supporting ISEV as a meeting sponsor.

11. The abstract title and text may not contain trade names. ISEV reserves the right to replace trade names in accepted abstracts.
12. Abstracts should be submitted in English.
13. Choose the preferred presentation mode: oral or poster. Oral presentation submissions will be considered for either oral or poster presentations. Poster presentation submissions will be considered for poster presentations only.

Abstract review, selection, and publication

An international panel of experts representing all subspecialties and geographical diversity will review all abstracts received. Each abstract will be reviewed by at least three reviewers, based on scientific novelty, completeness and including the MISEV2023 criteria where appropriate. The review will be “blinded”: that is, the reviewers will not have access to the names or institutions of the authors. The submitters and presenting authors will receive confirmation of acceptance for oral presentation, poster presentation, or a notice of rejection, by e-mail. No revisions can be made after the abstract deadline.

The highest ranked oral presentation preference abstracts will be selected for oral presentation. Authors of abstracts selected for oral presentation will be informed about the session and date of presentation, and presentation guidelines will be provided.

Poster presenters will be informed about the date of the poster session and will receive guidelines for preparation and presentation. High-quality abstracts accepted for poster presentation and submitted by junior investigators (<4 years after terminal degree) will also be considered for an oral lightning talk to accompany poster presentation.

All accepted abstracts will be published in The Journal of Extracellular Vesicles.

Withdrawal Policy

If authors wish to withdraw their abstracts from presentation or publication, they are requested to send an e-mail to ISEV (contact@isev.org) before 5 April 2027. All abstracts will be prepared for publication in The Journal of Extracellular Vesicles. Withdrawn abstracts cannot be presented or published.

ISEV2027 Abstract Themes

To aid the review process, you will be requested to select from one of the following themes which best fits with the content of your abstract.

(1) Foundational Biology

(2) Non-mammalian EVs

(3) Physiology and Disease Mechanisms

(4) Diagnostics and Prognostics

(5) Therapeutics and Application

(6) Technologies and Engineering

(1) Foundational Biology

EV Biogenesis (biosynthesis, cargo loading & release)

EV uptake mechanisms (endocytosis, etc.)

Surface and cargo analyses (DNA, RNA, protein, metabolites, glycosylation, etc.)

Extracellular particles (e.g., exomeres and supermeres)

EV corona

EV heterogeneity (atypical subtypes)

EV – Extracellular matrix / cell interactions and signaling

Milk EVs

(2) Non-mammalian EVs

Microbial EVs (bacteria, fungi, viruses)

Parasite-derived EVs

Plant & algae-derived EVs and other EV sources

Virus hijacking of EV secretion machinery

Environmental EVs

Dietary EVs

Evolution and comparative EV biology

(3) Physiology and Disease Mechanisms

Cancer initiation, progression & metastasis

Cell and tissue remodeling in disease

Fertility, reproduction and maternal-fetal interactions

Gastrointestinal system

Heart & vascular systems

Immunology & immunity

Infectious diseases and microbiomes

Kidney & urogenital tract

Metabolism and metabolic disorders

Musculoskeletal system

Nervous system and mental health

Pulmonary and respiratory systems

Developmental biology

Inter-kingdom interactions (host-microbe interactions, etc.)

Tissue EVs

Aging, senescence and rejuvenation

(4) Diagnostics and Prognostics

EV biomarkers in clinical studies and trials *

EV biomarkers – Cancer

EV biomarkers – Neurological disorders

EV biomarkers – Immunological and infectious disorders

EV biomarkers – Cardiovascular diseases

EV biomarkers – Other diseases

EV biomarkers – Tools

(5) Therapeutics and Application

EV-based therapeutics development – General aspects

EV PK/PD and biodistribution

EV therapeutics in clinical studies and trials *

EV therapeutics – Cancer

EV therapeutics – Neurological disorders

EV therapeutics – Immunological and infectious diseases

EV therapeutics – Cardiovascular diseases

EV therapeutics – Stem cells, regenerative medicine and wound healing

EV therapeutics – Other diseases

EV vaccines

EV therapeutics – Aging and rejuvenation

Regulatory science

EV quality control and standardization for manufacturing

Non-medical use (cosmetics, supplements, other consumer products)

Veterinary applications

(6) Technologies and Engineering

Artificial Intelligence and Computational Approaches in EV Science

- Deep learning for single-EV imaging and characterization
- Machine learning for EV biomarker discovery and multi-omics integration
- AI-guided EV engineering (cargo loading, targeting, bioprocess optimization)
- Computational modeling and EV data standards / open datasets

Artificial EVs (including EV mimetics and extruded EVs)

Virus-like particles

EV enrichment, isolation and purification

EV characterization, measurement, and standardization (single EVs)

EV detection, transfer analysis and reporter systems (single EVs)

EV imaging (live, single-EV imaging)

EV-based omics technologies

Novel functional assays of EVs

Artificial intelligence, data science

EV study models (organoids, etc.)

EV engineering (tissue targeting & display; surface chemistry & nanoengineering)

EV – Material hybrids and biomaterials

Hydrogels, scaffolds, coatings, and EV–nanoparticle/liposome hybrid constructs.

EV manufacturing and scale-up

****Studies requiring IRB Approval and Informed Consent***

Language setting of your keyboard

The keyboard configuration of computers in some countries may cause problems with the printing of the abstracts when certain characters are used. To avoid these problems the language setting of your computer may need to be changed. To do this select "Start" then "Settings", then "Control Panel" and then choose "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open your word processing software and set the font type to Arial. In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font, then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha'.